January to March 2025: HARTMANN again starts the financial year with good earnings

Heidenheim, 30 April 2025. HARTMANN has once again started the 2025 financial year with good earnings performance. Despite rising material prices and tariffs, the Company is maintaining its outlook for the year as a whole.

From January to March 2025, organic sales growth of 1.3% led to sales revenues of EUR 607.3 million.

Adjusted EBITDA of EUR 70.9 million was EUR 1.9 million higher than in the previous year. The adjusted EBITDA margin was 11.7%.

In the first quarter, some countries launched new products as part of the Transformation Program, which are expected to further contribute to sales growth over the course of the year.

The Incontinence Management segment once again registered growth – particularly for incontinence pants – in the most important European markets, including Germany, Spain and the Czech Republic.

In the Wound Care segment, silicone-based superabsorbent wound dressings contributed to ongoing growth, with the strategically important US market of particular note.

Performance in the Infection Management segment was varied: while sales in the areas of surface and hand disinfection increased, there was a decline in the trade business with personal protective equipment.

In the Complementary Group Divisions segment, the KOB and Kneipp Groups recorded growth. Sales for the CMC Group declined compared with the same period of the previous year.

HARTMANN is consistently implementing its Transformation Program in the current financial year. It is expected to contribute a further EUR 50 million to earnings, thus sustainably strengthening the Company’s competitiveness and resilience.

Despite challenging conditions, HARTMANN expects moderate organic sales growth and adjusted EBITDA in the range of EUR 260 to 300 million for the 2025 financial year.

Further information on the HARTMANN financial position can be found at https://corporate.hartmann.info/de-de/investor-relations.

The HARTMANN GROUP is one of the leading European providers of professional medical and care products and associated services. Every day, healthcare professionals and patients rely on HARTMANN brands in the segments of Incontinence Management (e.g. MoliCare®), Wound Care (e.g. Zetuvit®, Cosmopor®) and Infection Management (e.g. Sterillium®). This is expressed in our brand promise of “Helps. Cares. Protects.” Founded in 1818, the Company sells its products and solutions in 130 countries around the world.

To learn more about the HARTMANN GROUP, visit www.corporate.hartmann.info.